Diligent profiling of a clinical collection (repurposing) drug library using our discovery platform discovered a new class of small molecules with promising biological activities to treat a specific type of heart failure. Among them, two pipelines (IVS-201 and IVS-202) have been selected. Those pipelines have the potential to deliver better outcomes for patients fighting heritable monogenic heart disease without effective treatment.

IVS is expanding our collection of inherited heart failure models for target validation.  A new pipeline is expected shortly.   

Our pipeline of precision heart failure medicine drastically decreases the size of clinical trials and expect to reduce the cost of clinical trials at least ten times compared to the traditional approach.